Vectalys is currently the coordinator of the MAGenTA project for the development of innovative experimental models and clinical trials dedicated to urogenital diseases.
The MAGenTA project is a collaborative work between four SMEs and two academic institutions. The goal is to develop new and innovative predictive experimental models and to provide pharmaceutical companies and academic research with better tools that would facilitate the validation of candidate genes and the discovery of new molecules. MAGenTA also includes two clinical studies to validate the effectiveness of two therapeutic molecules for urogenital diseases. The project received the Cancer Bio Santé cluster label in Toulouse, France, in July 2012. It started in January 2013 and is due to run for 5 years with a total project funding of €22.5 million.
Vectalys coordinated the SHIP-In project to develop new and innovative cellular systems for the biopharmaceutical industry.
The SHIP-In project consisted in optimizing the new iPS cells technology to cover biopharmaceutical industry demand. The goal was to provide pharmaceutical and cosmetics companies with an unlimited supply of human cells meeting high quality criteria. SHIP-In facilitated the discovery of new molecules and generally sped up the therapeutic innovation process. Co-sponsored by France’s Cancer Bio Santé (Toulouse) and Medicen (Paris) research clusters, the project received the Alsace BioValley cluster’s label in Alsace, France, in November 2008.
Vectalys participated in LIV-ES, a European collaborative research project on the development of culture conditions for the differentiation of hES cells into hepatocytes.
LIV-ES’ goal was to develop innovative conditions and standardized protocols to provide a renewable source of human hepatocytes (liver cells) for the treatment of liver diseases. The final goal was to deliver a bank of fully mature human hepatocytes derived from hES cell lines developed by LIV-ES partners. The consortium brought together 9 internationally renowned research teams from France, United Kingdom, Spain, Finland and Israel.
Vectalys was involved in the development of new experimental models of urinary incontinence for the discovery and validation of new therapeutic targets, as part of the program 3SI phase 3.
The purpose of this project was to validate the implication of target genes in urinary pathologies. UROsphere brought its expertise in experimental models in vitro and in vivo techniques and functional pharmacology. Vectalys provided technological expertise in gene expression and tools for discovery and validation of genes. Together, thanks to the 3SI funding, we developed new animal models for the urogenital system and for validating new therapeutic targets.